Literature DB >> 19401453

Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells.

Changwan Hong1, Hyunji Lee, Yoon-Kyung Park, Junghoon Shin, Sundo Jung, Hoyeon Kim, Seokmann Hong, Se-Ho Park.   

Abstract

The physiologic function of natural killer T (NKT) cells in adaptive immunity remains largely unknown because most studies have used NKT cell agonists. In the present study, the role of NKT cells during the secondary effector phase was investigated separately from the primary immunization phase via adoptive transfer of differentiated effector T cells into naive recipients. We found that secondary antitumor CD8(+) T-cell responses were optimal when NKT cells were present. Tumor-specific CD8(+) effector T cells responded less strongly to tumor cell challenge in NKT cell-deficient recipients than in recipients with intact NKT cells. NKT cell-mediated enhancement of the secondary antitumor CD8(+) T-cell response was concurrent with increased number and activity of tumor-specific CD8(+) T cells. These findings provide the first demonstration of a direct role for NKT cells in the regulation of antigen-specific secondary T-cell responses without the use of exogenous NKT cell agonists such as alpha-galactosylceramide (alpha-GalCer). Furthermore, forced activation of NKT cells with alpha-GalCer during the secondary immune response in suboptimally immunized animals enhanced otherwise poor tumor rejection responses. Taken together, our findings strongly emphasize the importance of NKT cells in secondary CD8(+) T-cell immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401453     DOI: 10.1158/0008-5472.CAN-08-1721

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.

Authors:  Maciej Kmieciak; Debasmita Basu; Kyle K Payne; Amir Toor; Adly Yacoub; Xiang-Yang Wang; Lisa Smith; Harry D Bear; Masoud H Manjili
Journal:  J Immunol       Date:  2011-06-13       Impact factor: 5.422

2.  The requirement of natural killer T-cells in tolerogenic APCs-mediated suppression of collagen-induced arthritis.

Authors:  Sundo Jung; Yoon-Kyung Park; Jung Hoon Shin; Hyunji Lee; Soo-Young Kim; Gap Ryol Lee; Se-Ho Park
Journal:  Exp Mol Med       Date:  2010-08-31       Impact factor: 8.718

3.  Secretion of IFN-gamma but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen.

Authors:  Stephen R Mattarollo; Michelle Yong; Lieven Tan; Ian H Frazer; Graham R Leggatt
Journal:  J Immunol       Date:  2010-04-21       Impact factor: 5.422

4.  CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis.

Authors:  Laura M Hix; Yihui H Shi; Randy R Brutkiewicz; Paul L Stein; Chyung-Ru Wang; Ming Zhang
Journal:  PLoS One       Date:  2011-06-13       Impact factor: 3.752

5.  Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.

Authors:  Shalu Sharma Kharkwal; Christopher T Johndrow; Natacha Veerapen; Himanshu Kharkwal; Noemi A Saavedra-Avila; Leandro J Carreño; Samantha Rothberg; Jinghang Zhang; Scott J Garforth; Peter J Jervis; Lianjun Zhang; Alena Donda; Amareeta K Besra; Liam R Cox; Steven C Almo; Alan Howell; Elizabeth E Evans; Maurice Zauderer; Gurdyal S Besra; Steven A Porcelli
Journal:  Cancer Res       Date:  2021-01-22       Impact factor: 13.312

6.  Invariant NKT cells act as an adjuvant to enhance Th2 inflammatory response in an OVA-induced mouse model of asthma.

Authors:  Hanxiang Nie; Qiaoyu Yang; Guqin Zhang; Ailing Wang; Qing He; Min Liu; Ping Li; Jiong Yang; Yi Huang; Xuhong Ding; Hongying Yu; Suping Hu
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

7.  Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells.

Authors:  Shuichi Kitayama; Rong Zhang; Tian-Yi Liu; Norihiro Ueda; Shoichi Iriguchi; Yutaka Yasui; Yohei Kawai; Minako Tatsumi; Norihito Hirai; Yasutaka Mizoro; Tatsuaki Iwama; Akira Watanabe; Mahito Nakanishi; Kiyotaka Kuzushima; Yasushi Uemura; Shin Kaneko
Journal:  Stem Cell Reports       Date:  2016-02-09       Impact factor: 7.765

Review 8.  Invariant NKT cells as novel targets for immunotherapy in solid tumors.

Authors:  Karsten A Pilones; Joseph Aryankalayil; Sandra Demaria
Journal:  Clin Dev Immunol       Date:  2012-10-17

9.  B Cells Promote Th1- Skewed NKT Cell Response by CD1d-TCR Interaction.

Authors:  Jung Hoon Shin; Se-Ho Park
Journal:  Immune Netw       Date:  2013-10-26       Impact factor: 6.303

10.  Altered Hepa1-6 cells by dimethyl sulfoxide (DMSO)-treatment induce anti-tumor immunity in vivo.

Authors:  Zhengyu Jiang; Hongxia Zhang; Ye Wang; Bin Yu; Chen Wang; Changcheng Liu; Juan Lu; Fei Chen; Minjun Wang; Xinlu Yu; Jiahao Lin; Xinghua Pan; Pin Wang; Haiying Zhu
Journal:  Oncotarget       Date:  2016-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.